Table of contents


On 20 June 2005, orphan designation (EU/3/05/288) was granted by the European Commission to A Carlsson Research AB, Sweden, for 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HC1 for the treatment of Huntington's disease.

In June 2007, A Carlsson Research AB changed name to NeuroSearch Sweden AB.

The sponsorship was transferred to NSAB, Filial af NeuroSearch Sweden AB, Sverige, Denmark in July 2009 and subsequently to Teva Pharma GmbH, Germany, in April 2013.

The sponsorship was transferred to Teva GmbH, Germany, in November 2016.

The sponsorship was transferred to Clinical Technology Centre (Ireland) Limited, Ireland, in February 2019.

Key facts

Active substance
4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1
Disease / condition
Treatment of Huntington’s disease
Date of first decision
EU designation number

Sponsor's contact details

Clinical Technology Centre (Ireland) Limited
Building C1, Athlone Business and Technology Park
County Westmeath N37 TE84
Tel. +353 90 6460327

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating